---
title: "CVRx Q2 FY26 net loss narrows 4.76% to $14 million; revenue rises 16% to $15.7 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295144614.md"
description: "CVRx reported Q2 FY26 revenue of $15.7 million, up 16% YoY, with a narrowed net loss of $14 million. Gross margin improved to 87%. U.S. sales rose 21%, while European sales fell 31%. Active U.S. implanting centers reached 258, and Humana issued a Medicare Advantage coverage policy for Barostim. The company forecasted 2026 revenue between $58-$60 million, citing challenges from fewer sales territories and payer issues."
datetime: "2026-08-06T21:12:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295144614.md)
  - [en](https://longbridge.com/en/news/295144614.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295144614.md)
---

# CVRx Q2 FY26 net loss narrows 4.76% to $14 million; revenue rises 16% to $15.7 million

-   CVRx posted Q2 2026 revenue of $15.7 million, up 16% year over year; net loss narrowed to $14 million, or $0.53 a share. \* Gross margin rose 3 percentage points to 87%; gross profit climbed 20% to $13.7 million. \* U.S. revenue increased 21% to $14.8 million on 466 units; Europe revenue fell 31% to $0.9 million on 40 units. \* Active U.S. implanting centers grew to 258; Humana issued a Medicare Advantage coverage policy for Barostim effective May 1, 2026. \* Forecast 2026 revenue of $58 million-$60 million; CEO Kevin Hykes cited fewer sales territories, lower productivity, and a prolonged issue with a major payer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-092005), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CVRX.US](https://longbridge.com/en/quote/CVRX.US.md)
- [HUM.US](https://longbridge.com/en/quote/HUM.US.md)

## Related News & Research

- [CVRx Q2 revenue beats estimates, outlook cut on sales force, payer challenges](https://longbridge.com/en/news/295142307.md)
- [CVRx (NASDAQ:CVRX) Announces Quarterly Earnings Results](https://longbridge.com/en/news/295181057.md)
- [CVRx Stock Is Falling Overnight: Here's What's Driving the Move](https://longbridge.com/en/news/295191032.md)
- [CVRx CRO Robert John exits; Paul Verrastro named interim head of sales](https://longbridge.com/en/news/295526109.md)
- [Humana sets R$ 0.07 per unit distribution payable Aug. 6](https://longbridge.com/en/news/294827694.md)